Guardant Health acquired early cancer‑detection startup MetaSight Diagnostics for $59 million upfront plus up to $90 million in contingent payments, expanding its multiomics screening portfolio as the company pushes Shield, its FDA‑cleared colorectal cancer screening test. Guardant said the MetaSight technology complements Shield and will accelerate product development for broader screening offerings. Executives gave 2026 guidance that anticipates significant growth in screening revenue — projecting $162–$174 million and 210,000–225,000 Shield tests — driven by commercial partnerships and a planned integration with Quest Diagnostics. Management emphasized measured scaling and the need for guideline inclusion and payer coverage to unlock further adoption.